AU2012240424B2 - Hepatocyte growth factor mimics as therapeutic agents - Google Patents

Hepatocyte growth factor mimics as therapeutic agents Download PDF

Info

Publication number
AU2012240424B2
AU2012240424B2 AU2012240424A AU2012240424A AU2012240424B2 AU 2012240424 B2 AU2012240424 B2 AU 2012240424B2 AU 2012240424 A AU2012240424 A AU 2012240424A AU 2012240424 A AU2012240424 A AU 2012240424A AU 2012240424 B2 AU2012240424 B2 AU 2012240424B2
Authority
AU
Australia
Prior art keywords
hgf
isoleucine
group
cysteine
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012240424A
Other languages
English (en)
Other versions
AU2012240424A1 (en
Inventor
Caroline C. Benoist
Joseph W. Harding
Leen H. Kawas
Gary A. Wayman
John W. Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington State University WSU
Original Assignee
Washington State University WSU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington State University WSU filed Critical Washington State University WSU
Publication of AU2012240424A1 publication Critical patent/AU2012240424A1/en
Assigned to WASHINGTON STATE UNIVERSITY reassignment WASHINGTON STATE UNIVERSITY Request for Assignment Assignors: WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION
Application granted granted Critical
Publication of AU2012240424B2 publication Critical patent/AU2012240424B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
AU2012240424A 2011-04-02 2012-04-02 Hepatocyte growth factor mimics as therapeutic agents Active AU2012240424B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161471122P 2011-04-02 2011-04-02
US201161471124P 2011-04-02 2011-04-02
US61/471,124 2011-04-02
US61/471,122 2011-04-02
PCT/US2012/031815 WO2012138599A2 (en) 2011-04-02 2012-04-02 Hepatocyte growth factor mimics as therapeutic agents

Publications (2)

Publication Number Publication Date
AU2012240424A1 AU2012240424A1 (en) 2013-10-17
AU2012240424B2 true AU2012240424B2 (en) 2017-10-26

Family

ID=46969763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012240424A Active AU2012240424B2 (en) 2011-04-02 2012-04-02 Hepatocyte growth factor mimics as therapeutic agents

Country Status (8)

Country Link
US (3) US9150613B2 (https=)
EP (1) EP2709650B1 (https=)
JP (1) JP6173298B2 (https=)
CN (1) CN103582490B (https=)
AU (1) AU2012240424B2 (https=)
CA (1) CA2832113C (https=)
ES (1) ES2622385T3 (https=)
WO (1) WO2012138599A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014052766A1 (en) * 2012-09-27 2014-04-03 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN104788537B (zh) * 2015-03-31 2018-03-13 中国科学院长春应用化学研究所 一种四肽化合物及其制备方法和应用
US11021514B2 (en) * 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN110716925B (zh) * 2019-09-05 2023-08-04 中电科大数据研究院有限公司 一种基于轨迹分析的跨境行为识别方法
US20230000943A1 (en) * 2021-06-29 2023-01-05 Synaptogenix, Inc. Method of inducing synaptogenesis by administering angiotensin and analogues thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160585T1 (de) * 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
US5854388A (en) * 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
WO2011019400A2 (en) * 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARDING, J. W. et al. "Development of orally active Angiotensin IV analogs as anti-dementia drugs" Society for Neuroscience Abstract Viewer and Itinerary (January 2009) page 529.15 *
KAWAS, L. H. et al. "The angiotensin IV analogs D-Nle-X-Ile-NH-(CH2)5-COOH (6AH family) can act as Hepatocyte Growth Factor/c-Met modifiers" FASEB Journal vol. 25, April 2011, 1071.1 *

Also Published As

Publication number Publication date
US8598118B2 (en) 2013-12-03
WO2012138599A2 (en) 2012-10-11
EP2709650A2 (en) 2014-03-26
JP2014511858A (ja) 2014-05-19
US9150613B2 (en) 2015-10-06
NZ616210A (en) 2015-07-31
US20140088004A1 (en) 2014-03-27
EP2709650B1 (en) 2017-02-08
ES2622385T3 (es) 2017-07-06
CN103582490B (zh) 2015-09-30
WO2012138599A3 (en) 2013-01-17
JP6173298B2 (ja) 2017-08-02
CA2832113A1 (en) 2012-10-11
HK1196075A1 (en) 2014-12-05
EP2709650A4 (en) 2015-04-22
US20130165392A1 (en) 2013-06-27
US20170049843A1 (en) 2017-02-23
CN103582490A (zh) 2014-02-12
CA2832113C (en) 2020-07-21
AU2012240424A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
AU2012240424B2 (en) Hepatocyte growth factor mimics as therapeutic agents
Gudasheva et al. Low‐molecular mimetics of nerve growth factor and brain‐derived neurotrophic factor: Design and pharmacological properties
US20140094413A1 (en) Hepatocyte growth factor (hgf) mimics as therapeutic agents
EP0743955B1 (en) Cyclic nerve growth factor (ngf) structural analogs and their uses
Saragovi et al. Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites
US9051351B2 (en) Hepatocyte growth factor mimics as therapeutic agents
JP4944611B2 (ja) ニューロンの成長を調節する化合物およびそれらの使用
NZ616210B2 (en) Hepatocyte growth factor mimics as therapeutic agents
US20230095144A1 (en) Amyloid inhibitory peptides
KR102532557B1 (ko) Dsg2 유래 펩타이드
HK1196075B (en) Hepatocyte growth factor mimics as therapeutic agents
Class et al. Patent application title: HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS Inventors: Joseph W. Harding (Pullman, WA, US) John W. Wright (Pullman, WA, US) Caroline C. Benoist (Nashville, TN, US) Leen H. Kawas (Pullman, WA, US) Gary A. Wayman (Pullman, WA, US) Assignees: WASHINGTON STATE UNIVERSITY
US12384816B2 (en) Blood-brain barrier permeable peptide
EP4061394A1 (en) Oligopeptide that inhibits angiogenesis and vascular function
US20120114565A1 (en) Compounds modulators of vegf activity and uses thereof
Kawas Development of therapeutics targeting the hepatocyte growth factor (HGF)/MET system
Class et al. Patent application title: Hepatocyte Growth Factor Mimics as Therapeutic Agents Inventors: Joseph W. Harding (Pullman, WA, US) John W. Wright (Pullman, WA, US) Caroline C. Benoist (Nashville, TN, US) Leen H. Kawas (Pullman, WA, US) Gary A. Wayman (Pullman, WA, US) Assignees: WASHINGTON STATE UNIVERSITY
Harding et al. Number of Pages

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: WASHINGTON STATE UNIVERSITY

Free format text: FORMER APPLICANT(S): WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION

FGA Letters patent sealed or granted (standard patent)